Federated Hermes, Inc. Acadia Pharmaceuticals Inc Transaction History

Federated Hermes, Inc.

$43 Billion
Q4 2024

A detailed history of Federated Hermes, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 699 shares of ACAD stock, worth $13,945. This represents 0.0% of its overall portfolio holdings.

Number of Shares

699

Previous 1,095 36.16%

Holding current value

$13,945

Previous $16,000 25.0%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$14.29 - $18.76 $5,658 - $7,428	-396 Reduced 36.16%	699 $12,000
Q3 2024 Nov 13, 2024	SELL	$15.14 - $19.14 $2,271 - $2,871	-150 Reduced 12.05%	1,095 $16,000
Q2 2024 Aug 08, 2024	SELL	$14.62 - $18.42 $108,231 - $136,363	-7,403 Reduced 85.6%	1,245 $20,000
Q1 2024 May 14, 2024	SELL	$17.79 - $30.86 $1.49 Million - $2.58 Million	-83,695 Reduced 90.63%	8,648 $159,000
Q4 2023 Jan 31, 2024	SELL	$20.78 - $31.77 $361,031 - $551,971	-17,374 Reduced 15.84%	92,343 $2.89 Million
Q3 2023 Nov 13, 2023	BUY	$20.84 - $33.47 $2.01 Million - $3.22 Million	96,351 Added 720.87%	109,717 $2.29 Million
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $236,864 - $341,324	13,307 Added 22554.24%	13,366 $320,000
Q1 2023 May 08, 2023	SELL	$16.32 - $20.92 $489 - $627	-30 Reduced 33.71%	59 $1,000
Q4 2022 Feb 13, 2023	SELL	$14.2 - $18.63 $710 - $931	-50 Reduced 35.97%	89 $1,000
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $105,077 - $136,056	-7,447 Reduced 98.17%	139 $2,000
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $2.68 Million - $5.6 Million	-205,840 Reduced 96.45%	7,586 $107,000
Q1 2022 May 13, 2022	SELL	$20.94 - $27.5 $17.9 Million - $23.5 Million	-855,478 Reduced 80.03%	213,426 $5.17 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $6.75 Million - $10.9 Million	402,152 Added 60.32%	1,068,904 $24.9 Million
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $10.5 Million - $16.5 Million	666,752 New	666,752 $11.1 Million
Q2 2021 Aug 16, 2021	SELL	$19.4 - $27.42 $19.4 Million - $27.4 Million	-1,000,000 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$25.02 - $54.99 $25 Million - $55 Million	1,000,000 New	1,000,000 $25.8 Million
Q3 2020 Nov 12, 2020	SELL	$36.42 - $57.0 $121,315 - $189,867	-3,331 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$39.26 - $52.73 $130,775 - $175,643	3,331 New	3,331 $161,000
Q1 2020 May 13, 2020	SELL	$31.65 - $46.87 $2.66 Million - $3.94 Million	-84,108 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$36.21 - $51.4 $2.27 Million - $3.22 Million	-62,659 Reduced 42.69%	84,108 $3.6 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $1.22 Million - $2.41 Million	54,728 Added 59.46%	146,767 $5.28 Million
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $2.15 Million - $2.59 Million	92,019 Added 460095.0%	92,039 $2.46 Million
Q3 2018 Nov 13, 2018	BUY	$13.03 - $21.81 $260 - $436	20 New	20 $1,000
Q1 2018 May 09, 2018	SELL	$22.47 - $32.33 $1.57 Million - $2.27 Million	-70,088 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$26.84 - $39.14 $706,187 - $1.03 Million	-26,311 Reduced 27.29%	70,088 $0
Q3 2017 Nov 13, 2017	BUY	$29.49 - $38.37 $2.84 Million - $3.7 Million	96,399	96,399 $3.63 Million

Others Institutions Holding ACAD

# of Institutions

316

Shares Held

164M

Call Options Held

855K

Put Options Held

350K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.23B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Acadia Pharmaceuticals Inc Transaction History